Mar 9, 2026 02:30AM
Nov 10, 2025 02:00AM
Oct 30, 2025 02:30AM
Jun 26, 2025 01:30AM
Jun 12, 2025 01:02PM
Apr 7, 2025 02:14PM
Apr 4, 2024 03:12PM GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Mar 22, 2024 01:00PM
Jan 25, 2024 01:10PM
Nov 15, 2023 11:45AM
Nov 13, 2023 01:30AM
Oct 26, 2023 12:23PM
Sep 27, 2023 01:30AM
Sep 18, 2023 01:30AM GenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP Batch
Sep 15, 2023 11:45AM
Jul 20, 2023 01:30AM
Apr 20, 2023 01:37PM
Mar 13, 2023 02:30AM
Mar 7, 2023 01:30AM
Jan 26, 2023 01:30AM
Jan 18, 2022 01:30AM GenSight Biologics Reports Cash Position as of December 31, 2021, and Provides Operational Update
Dec 14, 2021 01:30AM
Nov 30, 2021 01:30AM
Nov 22, 2021 01:30AM
Nov 12, 2021 01:30AM
Oct 12, 2021 01:30AM
Jul 29, 2021 01:30AM
Jun 30, 2021 01:30AM GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
May 14, 2021 01:30AM
Mar 10, 2021 01:30AM
Feb 15, 2021 01:30AM
Jan 19, 2021 01:30AM
Nov 3, 2020 01:30AM
Oct 15, 2020 01:30AM
Sep 21, 2020 01:30AM GenSight Biologics Reports New Analysis Demonstrating Statistically Significant and Clinically Meaningful Difference Between Visual Outcomes in LUMEVOQ®-Treated Patients and Natural History of Leber
Sep 15, 2020 01:30AM
Apr 6, 2020 01:30AM
Jan 21, 2020 01:30AM
Oct 22, 2019 01:30AM
Sep 23, 2019 01:30AM
Jul 24, 2019 12:02PM
Jul 11, 2019 12:24PM GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule
Jun 19, 2019 01:30AM
May 29, 2019 01:30AM
May 15, 2019 01:30AM
Sep 13, 2018 01:30AM
Jun 20, 2018 02:18AM
Jun 12, 2018 01:30AM
Jan 31, 2017 01:30AM GenSight Biologics Receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

325,492 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All